Cognitive disorders involve disturbances in information processing and integration associated with cognitive impairment and/or progressive cognitive decline.
Translational EEG biomarkers represent powerful means to measure procognitive or anti-psychotic treatments efficacy.

Our programs feature

  • Expertise in developping models of cognitive impairment
  • Selection of appropriate methods that translate into the clinic (Auditory-evoked potentials, pharmaco-induced models)
  • Specific skills in analyzing complex data sets
  • Personnalized support in selecting the best study design
Applications include: Autism spectrum disorders (ASD), Schizophrenia, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Epilepsy

Biomarkers: ASSR, ERPs, EROs, MMN, Gating, Multisite Coherence

Models: NMDA antagonists, Scopolamine. For other models, please contact us.

Programs: Lead selection (screening of small libraries of compounds), lead validation (dose-response effect, pharmacokinetic), rodent model phenotyping

Please take a moment to read our article: Improving Early Decision-Making in Schizophrenia